Myriad Genetics buy DerAlmanach100000
Start price
23.11.25
/
100%
€6.30
Target price
23.11.28
-
Performance (%)
-42.22%
Price
09:46
?
Summary
This prediction is currently active. Massive losses of -42.22% have been the result for the BUY prediction by DerAlmanach100000. This prediction currently runs until 23.11.28. The prediction end date can be changed by DerAlmanach100000 at any time. DerAlmanach100000 has 100% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Myriad Genetics | -10.294% | -10.294% |
| iShares Core DAX® | 2.554% | 0.562% |
| iShares Nasdaq 100 | 2.742% | -0.599% |
| iShares Nikkei 225® | 6.584% | 4.336% |
| iShares S&P 500 | 1.930% | -0.507% |
According to DerAlmanach100000 what are the pros and cons of Myriad Genetics for the foreseeable future?
Pros
Revenue growth > 30% per year expected
EBIT growth > 30% per year expected
Rising EBIT margin expected
Undervalued
Very Future proof/growth oriented business model
Market Leader or Top 3
Cons
Comments by DerAlmanach100000 for this prediction
Stopped prediction by DerAlmanach100000 for Myriad Genetics
Myriad Genetics
Start price
Target price
Perf. (%)
€4.44
05.06.25
05.06.25
-
05.06.28
05.06.28
8.56%
06.08.25
06.08.25
Revenue growth > 30% per year expected
EBIT growth > 30% per year expected
Rising EBIT margin expected
Undervalued
Myriad Genetics
Start price
Target price
Perf. (%)
€4.34
03.06.25
03.06.25
-
03.07.25
03.07.25
8.29%
04.06.25
04.06.25
Revenue growth > 30% per year expected
EBIT growth > 30% per year expected
Rising EBIT margin expected
Undervalued
Myriad Genetics
Start price
Target price
Perf. (%)
€3.60
17.05.25
17.05.25
-
17.05.28
17.05.28
6.67%
28.05.25
28.05.25
Revenue growth > 30% per year expected
EBIT growth > 30% per year expected
Rising EBIT margin expected
Undervalued